explore -WSS

explore

author：explore 2025-09-30 18:42:49 - browse：42747

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： EU regulator recommends expanding Mounjaro approval to obesity

WSS

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

eGenesis tests gene

3 hurdles to bringing medical devices to the U.S. market

Cloning humans is technically possible. It's curious no one has tried

Independent physicians launch a new lobbying group

The battle over the Brookhaven Landfill on Long Island

hotspot

explore

hotspot

How to save PrEP access — and even expand it

The story of mRNA: From a loose idea to a tool that may help curb Covid

Hepatitis C has a cure — but many Americans still lack access to it

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

The high cost of giving birth even with insurance

Death of patient in Alzheimer’s trial raises question of possible risks

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why drug prescriptions should include diagnoses

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Weight bias in eating disorder treatment complicated by new weight loss drugs

focus

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

The strategy behind pharma's lawsuits over drug pricing reform

Why drug prescriptions should include diagnoses

eGenesis tests gene

Paxlovid study fails to answer questions over benefit for broader groups

Weight bias in eating disorder treatment complicated by new weight loss drugs

Wikipedia

focus

Wikipedia

knowledge